BrainStorm Cell Therapeutics GAAP EPS of -$0.77

* BrainStorm Cell Therapeutics press release [https://seekingalpha.com/pr/20200769-brainstorm-cell-therapeutics-announces-second-quarter-2025-financial-results-and-provides] (OTC:BCLI [https://seekingalpha.com/symbol/BCLI]): Q2 GAAP EPS of -$0.77.
* Cash, cash equivalents, and restricted cash were approximately $1.03 million as of June 30, 2025.

MORE ON BRAINSTORM CELL THERAPEUTICS

* Brainstorm Cell Therapeutics Inc. (BCLI) Q1 2025 Earnings Call Transcript [https://seekingalpha.com/article/4788173-brainstorm-cell-therapeutics-inc-bcli-q1-2025-earnings-call-transcript]
* BrainStorm Cell Therapeutics Q2 2025 Earnings Preview [https://seekingalpha.com/news/4484849-brainstorm-cell-therapeutics-q2-2025-earnings-preview]
* BrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down [https://seekingalpha.com/news/4468668-brainstorm-cell-therapeutics-to-move-from-nasdaq-to-otcqb-after-delisting-shares-down]
* Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics [https://seekingalpha.com/symbol/BCLI/ratings/quant-ratings]
* Historical earnings data for BrainStorm Cell Therapeutics [https://seekingalpha.com/symbol/BCLI/earnings]